MH002, an Optimized Consortia Therapeutic for Inflammatory Bowel Diseases, Combines Clinical Efficacy with an Excellent Safety Profile in a Phase 2a Study in Ulcerative Colitis

Time: 12:00 pm
day: Day 2 Track A AM


  • MH002, a 6-strain consortia therapeutic designed, optimized and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis
  • Receive first-time insight in the integrated data from a placebo-controlled randomized phase 2a study of MH002 in Ulcerative Colitis patients, combining clinical efficacy and safety profile